2018
DOI: 10.1177/2047487318792626
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: In this observational study, we compared the effect of lipoprotein apheresis and evolocumab or alirocumab on levels of lipoprotein cholesterol, triglycerides and inflammatory markers (C reactive protein and interleukin 6) in cardiovascular patients ( n = 9). Patients were monitored during the last year of lipoprotein apheresis followed by six months of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors. The biochemical parameters were determined pre- and post- every apheresis procedure for… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
21
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(21 citation statements)
references
References 56 publications
0
21
0
Order By: Relevance
“…In addition, neither lipoprotein apheresis nor PCSK9 inhibition had any effect on interleukin (IL)-6 levels. 22 Since the present study has a small sample size, it should be viewed as hypothesis-generating. In addition, the patients were older and prevalently male.…”
mentioning
confidence: 90%
See 3 more Smart Citations
“…In addition, neither lipoprotein apheresis nor PCSK9 inhibition had any effect on interleukin (IL)-6 levels. 22 Since the present study has a small sample size, it should be viewed as hypothesis-generating. In addition, the patients were older and prevalently male.…”
mentioning
confidence: 90%
“…21 The observational study by Zenti et al presented in the November issue of the European Journal of Preventive Cardiology, investigated the efficacy of a treatment comprised of switching from apheresis to PCSK9 inhibitors. 22 The study group included nine patients with FH and cardiovascular disease. The endpoint was the effect of treatment on lipid profile and inflammatory markers.…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…Within just 12 years from the gene discovery, two PCSK9 inhibitors could receive United States of America Food and Drug Administration approval for the treatment of familial hypercholesterolemia and have been shown to be equivalent in reducing LDL and superior in increasing highdensity lipoprotein levels as compared to lipoprotein apheresis. 2,3 In brief, PCSK9 binds to LDL receptors and causes their destruction within lysosomes. Its inhibition would result in the recycling of LDL receptors, which leads to the internalization of more LDL cholesterols and a reduction in the blood levels of LDL.…”
mentioning
confidence: 99%